Fabian Finkelmeier
Frankfurt Am Main, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.
Journal: ESMO gastrointestinal oncology
Published: May 22, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.
Journal: International journal of cancer
Published: March 23, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.
Journal: International journal of cancer
Published: February 15, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 07, 2026
High-power microwave ablation with preablation transarterial chemoembolization enhances ablation zone stability in patients with liver malignancies.
Journal: La Radiologia medica
Published: October 25, 2025
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.
Journal: JHEP reports : innovation in hepatology
Published: September 24, 2025
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab.
Journal: Targeted oncology
Published: September 18, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Journal: Journal for immunotherapy of cancer
Published: August 31, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 01, 2025
Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.
Journal: JHEP reports : innovation in hepatology
Published: July 15, 2025
Last Updated: 09/26/2026